SpaceOAR® Hydrogel News
Augmenix, UK Ltd. Launches New UK SpaceOAR Hydrogel Website
Augmenix has launched a dedicated UK website to support the growing number of clinicians and patients who are using SpaceOAR® hydrogel to help reduce unnecessary and life-changing side-effects from prostate cancer radiotherapy.
Throughout the UK over 45,000 men are diagnosed with prostate cancer every year.1 This means about 1 in 8 men will get prostate cancer at some point in their lives.2 Many patients are treated successfully with different forms of radiotherapy, but there are known side-effects such as rectal bleeding, rectal pain, impaired sexual function, and faecal and urinary incontinence that result from radiation damage to the organs and tissues surrounding the prostate. SpaceOAR Hydrogel is a soft, implantable gel which is placed with a minimally invasive procedure and is clinically proven to reduce the short and long-term side-effects of radiation exposure.
“The development of a UK centric website provides doctors in the UK and Ireland more clinical information, materials and tools on both the application and benefits of SpaceOAR. Helping them make a difference to men undergoing radiotherapy.” said Stephen McGill, Vice President and General Manager of Augmenix International.
“This website will also provide patients with resources and information to support their journey with SpaceOAR hydrogel during radiotherapy. Due to the high level of media interest on hydrogel spacing, we have invested in building an online ‘find a hospital tool’. This online tool is integrated into the website and will allow patients to conduct their own research and search for private and public hospitals who have setup SpaceOAR implantation services.”
1. Prostate Cancer UK. 2018. About Prostate Cancer. [ONLINE] Available at: http://www.prostatecanceruk.org/prostate-information/about-prostate-cancer. [Accessed 15 October 2018].
2. Cancer Research UK. 2018. Prostate Cancer Statistics. [ONLINE] Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer. [Accessed 15 October 2018].
New treatment reduces side-effects of radiotherapy in prostate cancer patients
Prostate cancer patients at The London Clinic are some of the first in the UK to be treated with a new high-tech gel that has been designed to protect men from the side-effects of radiotherapy treatment that can cause long-term problems such as rectal damage.
GenesisCare UK and Augmenix UK Ltd. Announce UK Partnership
GenesisCare UK and Augmenix UK Ltd. announce a partnership to provide access to SpaceOAR Hydrogel, a minimally invasive hydrogel spacer, which lasts the duration of therapy and is proven to decrease unwanted side effects from radiotherapy treatment in patients with prostate cancer.
New UK Headquarters
Augmenix, Inc., a worldwide leader in hydrogel spacing solutions which reduces toxicity associated with radiation therapy, has opened a new UK company headquarters, Augmenix UK Ltd., in Corby, Northamptonshire, England.
Prostate Cancer Radiotherapy in Japan
An Update From Stephen McGill, Vice President and General Manager International.
I am delighted that SpaceOAR hydrogel is now available through the MHLW national reimbursement programme for all men undergoing prostate cancer radiotherapy treatment throughout Japan. I truly believe the commitment of the Japanese MHLW to reimburse SpaceOAR is a substantial leap forward to improving radiotherapy outcomes and reducing the associated risks.
UsToo and Dr. Daniel Fried Present Live Webcast and Q and A on Prostate Cancer Radiation Therapy
The event featured a presentation from renowned radiation oncologist Daniel B. Fried, MD, MPH, PhD, who practices at the Gibbs Cancer Center and Research Institute in Greenville, S.C discussing radiation therapy as an option for prostate cancer treatment.
The Relaunch of SpaceOAR Hydrogel Clinical Publications!
Now it’s easier than ever to find the peer-reviewed papers, abstracts and posters that evaluate the efficacy of SpaceOAR hydrogel.